Telix Pharmaceuticals Limited

Telix today announces that Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection*) in selecting patients for PSMA-targeted radionuclide therapy. Illuccix remains the only PSMA-PET agent approved in Australia, manufactured to good manufacturing practice (GMP) standards, and listed on the Medicare Benefits Schedule for imaging patients with prostate cancer. Label expansion means that Illuccix is now approved to select patients with metastatic prostate cancer, for treatment with 177-Lu vipivotide tetraxetan, the only PSMA-targeted lutetium therapy registered in Australia. This expands the clinical utility for Illuccix and will further improve access to advanced prostate cancer imaging for Australian men. Read more on our website here: https://bit.ly/3ZVKbQz *also known as Ga-68 Glu-urea-Lys(ahx)-hbed-CC.

During #NuclearMedicineWeek we recognise and express our gratitude to the many professionals that make nuclear medicine possible. Thank you for your contributions to advancing the field and improving outcomes for patients. Visit the Society of Nuclear Medicine and Molecular Imaging (SNMMI) website for more on the history and purpose behind this annual event: https://bit.ly/4eTkxA9 To learn more about how Telix is harnessing targeted radiation and precision oncology to help patients live longer, better quality lives, visit: https://bit.ly/4eRMuIF

Telix today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA-targeted radionuclide therapy. Label expansion means that Illuccix is now approved to select patients, with progressive metastatic castration-resistant prostate cancer, for treatment with 177-Lu vipivotide tetraxetan, the only PSMA-targeted lutetium therapy registered in Canada. This expands the clinical utility for Illuccix and will further improve access to advanced prostate cancer imaging for Canadian men. Read more on our website here: https://bit.ly/3TR1hLF

A huge shoutout to our incredible employees who participated in Prostate Cancer Awareness Month events during September! 💙 In the US, Telix is a proud supporter of the ZERO Prostate Cancer Run/Walks which help to fund critical research and care for men with prostate cancer. Thank you to #TeamTelix, along with their family and friends, for getting behind this important cause. #PCAM #ZEROout

Telix today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET agent, TLX250-CDx in recurrent clear cell renal cell carcinoma (ccRCC) after surgery. The CA-NINE trial, led by Prof Brian Shuch at UCLA, will investigate the diagnostic performance of TLX250-CDx PET/CT in intermediate-to-high risk ccRCC post-surgery to identify the cancer where it has recurred, including metastatic disease. The investigator-initiated trial is one of multiple trials either underway or planned, which may inform future label expansion for TLX250-CDx. To read more visit our website here: https://bit.ly/3XO861z TLX250-CDx has not received a marketing authorisation in any jurisdiction.

As a former U.S. Navy fighter pilot, Michael Crosby had faced many traumatic situations, but nothing could have prepared him for the moment his doctor said the word "cancer.“ Through his own experience, Mike recognized there was a lack of awareness amongst Veterans about their increased risk of prostate cancer and set out to do something about it by establishing a patient advocacy organization called Veterans Prostate Cancer Awareness. During Prostate Cancer Awareness Month, Telix is sitting down with patients, advocates and physicians to shed light on the current unmet needs in prostate cancer. To read more about what Mike and Telix are doing to help patients visit: https://lnkd.in/gWTGbgSN

Telix today announces an agreement to acquire RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals. The acquisition significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners. This is aligned to Telix’s investment strategy around vertically integrated supply chain, manufacturing, and distribution, and will enable the delivery of key therapeutic and diagnostic isotopes alongside finished unit doses in relevant markets. Read more on our website here: https://bit.ly/4gvjpnT Closing of the transaction is subject to customary conditions.

Thank you to the Wallonia Export & Investment Agency (AWEX) for recognising Telix with the Foreign Investment Award at this week’s 2024 Wallonia International Business Awards – an event instigated to celebrate companies operating in the Wallonia region of Belgium that have achieved remarkable performance. Telix has a significant manufacturing presence in Belgium, with sites in Seneffe, Herstal and Liège. We thank the Walloon regional government and AWEX for their continued support of Telix and radiopharmaceuticals - innovation which is positively impacting the lives of patients worldwide. Watch Telix’s award video here: https://bit.ly/4e8vbD0

Telix today announces that it has selected Cardinal Health as a commercial distributor to supply finished unit doses of its PET agent, Zircaix® (TLX250-CDx) for the imaging of kidney cancer in the United States. Through their extensive nuclear pharmacy network, the relationship with Cardinal Health has been central to the commercial success of Illuccix® and, subject to regulatory approval, we look forward to adding Zircaix® to their U.S. roster. To read the full announcement, visit our website: https://bit.ly/4daNxly

As a prostate cancer survivor and now a patient advocate, Dr Eddie Wright Snr has always been focused on fighting one thing - fear. It’s what he first felt at diagnosis, and what he believes stops many men from getting tested and diagnosed early. Now, through his patient organization, the We Can Win Foundation, he’s on a mission to change men’s mindsets about prostate cancer. During Prostate Cancer Awareness Month, Telix is sitting down with physicians, advocates and patients to shed light on the current unmet needs in prostate cancer. To read more about what Eddie and Telix are doing to help patients visit: https://bit.ly/47nVClA